|
|
WelcomeWorld Pharma News is an ambitious online news service dedicated to the world pharmaceutical industry. Our main goal is to keep our readers informed about the latest worldwide pharmaceutical news, realizations and achievements.
Register now to be in touch with our last developments and achievements or Subscribe to World Pharma News alerts by Email (a free e-mail delivery powered by Google).
Non progredi est regredi. |
||||
PharmaNews.eu, an advanced web based news project, targeting the European pharmaceutical domain, has been launched. The project was developed to directly connect, promote and disseminate the European pharmaceutical achievements...For further information, please visit http://www.pharmanews.eu |
|||||
Pharmaceutical Companies[ A | B | C | D | E | F | G | H | I | J | K | L | M | N | O | P | Q | R | S | T | U | V | W | X | Z ]Sponsored AdsPharmaceutical RSS NewsStart your day with worldwide pharmaceutical news[ Amgen | AstraZeneca | Boehringer Ingelheim | Bristol-Myers Squibb | GlaxoSmithKline | Janssen-Cilag | Johnson & Johnson | Novartis | Novo Nordisk | Pfizer | Roche | Shire | Takeda ]  European Commission - Pharmaceuticals US Food and Drug Administration
World Pharma News .net / Published NewsSponsored Ads |
Corporate News Channel
|
|||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
GlaxoSmithKline has announced a new global policy to voluntarily stop all corporate political contributions. In the past, GSK - in common with many companies and in full compliance with local laws - has made a number of corporate contributions in countries such as the US and Canada. GSK's new policy will ensure that no such contributions will be made in the future. 
AstraZeneca and Bristol-Myers Squibb have announced expansion of their worldwide collaboration to include the development and commercialisation of dapagliflozin in Japan. Dapagliflozin, one of two investigational drugs under joint development by the companies, is currently being studied in Phase III clinical trials in several countries, including the U.S., to assess its efficacy and safety as a once-daily treatment for type 2 diabetes. 
Novo Nordisk has announced that it will provide diabetes care, including free insulin, to 10,000 children in some of the world's poorest countries. The five-year programme, called 'Changing the Future for Children with Diabetes', will begin in 2009 with an initial roll-out in Uganda, Tanzania, Guinea-Conakry and the Democratic Republic of Congo. 
Pfizer Ltd (NYSE:PFE) (LSE:PFZ) and UCB have announced the formation of Cyclofluidic, a breakthrough technology company established with the aim of significantly accelerating the drug discovery process by allowing researchers to test a greater range of potential new medicines in a shorter time. 
Scrupulously researched articles dealing with a topic from the worlds of medicine or health care - articles written in a critical, comprehensible, yet objective manner - have an excellent
chance of winning the 2008 European Journalists' Prize. The award, which is sponsored by Bayer HealthCare AG, Leverkusen/Germany, is endowed with EUR 7,500. 
Genzyme Corporation (Nasdaq: GENZ) has announced that scientists have again named the company a top employer in a survey ranking the reputations of biotechnology and pharmaceutical companies. This year Genzyme moved up in the ranking to third on the global list of nearly 500 companies, the highest ranking it has ever earned. 
